Literature DB >> 18175283

Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes.

Maha Othman1.   

Abstract

Platelet-type von Willebrand disease (PT-VWD, or pseudo-VWD) and type 2B VWD share a common bleeding phenotype with different etiologies. Both PT-VWD and type 2B VWD represent an enhanced binding between the plasma von Willebrand factor (VWF) to its platelet ligand, glycoprotein Ib alpha ( GP1BA). However, type 2B VWD results from a functionally abnormal VWF molecule, whereas PT-VWD is caused by hyperresponsive platelets due to defects in the platelet GP1BA gene. The laboratory discrimination between the two disorders can be a challenge because simple phenotypic testing will not differentially identify the disorders, and the more complex testing approaches are often poorly applied. Definitive diagnosis is critical for treatment decisions and can be most definitively achieved by identifying the gene defect at either the VWF or GP1BA loci. A systematic international molecular genetic study would be helpful to address the question of whether PT-VWD is being misdiagnosed as type 2B VWD. Such a study can be facilitated by an international online database/disease registry to enhance international awareness about this otherwise long-recognized diagnostic dilemma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18175283     DOI: 10.1055/s-2007-1000368

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  7 in total

1.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

Review 2.  Genetic sequence analysis of inherited bleeding diseases.

Authors:  Flora Peyvandi; Tom Kunicki; David Lillicrap
Journal:  Blood       Date:  2013-10-11       Impact factor: 22.113

Review 3.  Molecular testing for disorders of hemostasis.

Authors:  D Lillicrap
Journal:  Int J Lab Hematol       Date:  2013-06       Impact factor: 2.877

Review 4.  The molecular characterization of von Willebrand disease: good in parts.

Authors:  P D James; D Lillicrap
Journal:  Br J Haematol       Date:  2013-02-14       Impact factor: 6.998

Review 5.  von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy.

Authors:  David Lillicrap
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

6.  Type 2B von Willebrand disease associated with the release of platelet agglutinates from megakaryocytes in the bone marrow.

Authors:  William B Slayton; Milin Patel; Martha Sola-Visner; Neil Harris; Angela Rivers; Robert R Montgomery; Kenneth D Friedman
Journal:  J Pediatr Hematol Oncol       Date:  2008-09       Impact factor: 1.289

7.  Clinical management, ethics and informed consent related to multi-gene panel-based high throughput sequencing testing for platelet disorders: Communication from the SSC of the ISTH.

Authors:  Kate Downes; Pascal Borry; Katrin Ericson; Keith Gomez; Andreas Greinacher; Michele Lambert; Eva Leinoe; Patrizia Noris; Chris Van Geet; Kathleen Freson
Journal:  J Thromb Haemost       Date:  2020-10       Impact factor: 5.824

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.